Hansoh Pharmaceutical Group Co Ltd (3692:HK) Stock Forecast
Alert
Its only available to paid users.
N/A
Based on the Hansoh Pharmaceutical Group Co Ltd stock forecast from 0 analysts, the average analyst target price for Hansoh Pharmaceutical Group Co Ltd is not available over the next 12 months. Hansoh Pharmaceutical Group Co Ltd’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Hansoh Pharmaceutical Group Co Ltd is Slightly Bearish, which is based on 6 positive signals and 9 negative signals. At the last closing, Hansoh Pharmaceutical Group Co Ltd’s stock price was HKD 18.80. Hansoh Pharmaceutical Group Co Ltd’s stock price has changed by +2.73% over the past week, +3.75% over the past month and +33.71% over the last year.
No recent analyst target price found for Hansoh Pharmaceutical Group Co Ltd
No recent average analyst rating found for Hansoh Pharmaceutical Group Co Ltd
Company Overview Hansoh Pharmaceutical Group Co Ltd
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-tumor, anti-infection, central nervous system diseases, oncology, metabolic and autoimmune diseases, etc. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Hengmu, Mailingda, Hengsen, XINYUE, Saint Luolai, Fulaimei, Pulaitan, Tanneng, Ameining, Oulanning, Ruibote, Fulaidi, Fulairui, and Puruian tablets. The company serves pharmaceutical product distributors. It has licence agreements with GSK plc to develop, manufacture, and commercialise HS20089 and HS-20093; GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089; and Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product, as well as collaboration agreement with Antengene Corporation Limited to commercialize selinexor and any product containing or comprising Selinexor. In addition, it engages in trading business. The company was founded in 1995 and is headquartered in Shanghai, the People's Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd. Read Less
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-tumor, anti-in...Read More
Frequently Asked Questions About Hansoh Pharmaceutical Group Co Ltd (3692:HK) Stock
Stock Target Advisor's fundamental analysis for Hansoh Pharmaceutical Group Co Ltd's stock is Slightly Bearish.
3692:HK stock's dividend yield is 1.73%.
Our analysis grades 3692:HK stock's dividend yield at F. This means that 3692:HK stock's dividend yield is above 8% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the HK exchange.
Based on this 3692:HK may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on 3692:HK's stock to indicate what its average analyst target is.
3692:HK stock's Price/Earning ratio is 24.44.
Our analysis grades 3692:HK stock's Price / Earning ratio at F. This means that 3692:HK stock's Price/Earning ratio is above 85% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the HK exchange.
Based on this 3692:HK may be a overvalued for its sector.
The last closing price of 3692:HK's stock was HKD 18.80.
The most recent market capitalization for 3692:HK is HKD 117.50B.
Unfortunately we do not have enough analyst data on 3692:HK's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Hansoh Pharmaceutical Group Co Ltd's stock.
As per our most recent records Hansoh Pharmaceutical Group Co Ltd has 9,099 Employees.
Hansoh Pharmaceutical Group Co Ltd's registered address is 287 Xiangke Road, Shanghai, China, 201210.
You can get more information about it from Hansoh Pharmaceutical Group Co Ltd's website at https://www.hspharm.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Hansoh Pharmaceutical Group Co Ltd (3692:HK) Stock
Stock Target Advisor's fundamental analysis for Hansoh Pharmaceutical Group Co Ltd's stock is Slightly Bearish.
3692:HK stock's dividend yield is 1.73%.
Our analysis grades 3692:HK stock's dividend yield at F. This means that 3692:HK stock's dividend yield is above 8% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the HK exchange.
Based on this 3692:HK may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on 3692:HK's stock to indicate what its average analyst target is.
3692:HK stock's Price/Earning ratio is 24.44.
Our analysis grades 3692:HK stock's Price / Earning ratio at F. This means that 3692:HK stock's Price/Earning ratio is above 85% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the HK exchange.
Based on this 3692:HK may be a overvalued for its sector.
The last closing price of 3692:HK's stock was HKD 18.80.
The most recent market capitalization for 3692:HK is HKD 117.50B.
Unfortunately we do not have enough analyst data on 3692:HK's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Hansoh Pharmaceutical Group Co Ltd's stock.
As per our most recent records Hansoh Pharmaceutical Group Co Ltd has 9,099 Employees.
Hansoh Pharmaceutical Group Co Ltd's registered address is 287 Xiangke Road, Shanghai, China, 201210.
You can get more information about it from Hansoh Pharmaceutical Group Co Ltd's website at https://www.hspharm.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 3692:HK !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
